| Jennifer Ann Tarpenning, MD | |
|
1555 Northway Dr Ste 200, Saint Cloud, MN 56303-4913 | |
| (320) 240-3157 | |
| Not Available |
| Full Name | Jennifer Ann Tarpenning |
|---|---|
| Gender | Female |
| Speciality | Family Medicine |
| Location | 1555 Northway Dr Ste 200, Saint Cloud, Minnesota |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1093336299 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 71875 (Minnesota) | Primary |
| Entity Name | Centracare Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1043212665 PECOS PAC ID: 2466363395 Enrollment ID: O20031105000293 |
News Archive
Although cannabis, also known as marijuana, has been shown to impair memory, reaction time and attention, it is difficult to assess this impairment in a natural setting. Researchers have developed a prototype app called 'Am I Stoned' that could help cannabis users understand how the drug is affecting them through a series of phone-based tasks.
Researchers at the Shiley-Marcos Alzheimer's Disease Research Center at the University of California San Diego are about to launch a Phase 2 clinical trial to test a gene therapy treatment for Alzheimer's disease (AD) called CERE-110.
Bayer HealthCare and Onyx Pharmaceuticals today announced that Bayer HealthCare has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the oral multi-kinase inhibitor regorafenib for the treatment of metastatic and/or unresectable gastrointestinal stromal tumors (GIST) in patients whose disease has progressed despite prior treatment.
Quidel Corporation (NASDAQ: QDEL), a global leader in point-of-care (POC) rapid diagnostic tests, received Special 510(k) clearance for an update to the Company's QuickVue® Influenza A+B test package insert to include reactivity with culture isolates of the 2009 H1N1 Influenza A virus.
› Verified 7 days ago
| Entity Name | Centracare Health System - Melrose |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1720045073 PECOS PAC ID: 1658270368 Enrollment ID: O20031231000690 |
News Archive
Although cannabis, also known as marijuana, has been shown to impair memory, reaction time and attention, it is difficult to assess this impairment in a natural setting. Researchers have developed a prototype app called 'Am I Stoned' that could help cannabis users understand how the drug is affecting them through a series of phone-based tasks.
Researchers at the Shiley-Marcos Alzheimer's Disease Research Center at the University of California San Diego are about to launch a Phase 2 clinical trial to test a gene therapy treatment for Alzheimer's disease (AD) called CERE-110.
Bayer HealthCare and Onyx Pharmaceuticals today announced that Bayer HealthCare has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the oral multi-kinase inhibitor regorafenib for the treatment of metastatic and/or unresectable gastrointestinal stromal tumors (GIST) in patients whose disease has progressed despite prior treatment.
Quidel Corporation (NASDAQ: QDEL), a global leader in point-of-care (POC) rapid diagnostic tests, received Special 510(k) clearance for an update to the Company's QuickVue® Influenza A+B test package insert to include reactivity with culture isolates of the 2009 H1N1 Influenza A virus.
› Verified 7 days ago
| Entity Name | Centracare Health System - Melrose |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1720045073 PECOS PAC ID: 1658270368 Enrollment ID: O20060504000839 |
News Archive
Although cannabis, also known as marijuana, has been shown to impair memory, reaction time and attention, it is difficult to assess this impairment in a natural setting. Researchers have developed a prototype app called 'Am I Stoned' that could help cannabis users understand how the drug is affecting them through a series of phone-based tasks.
Researchers at the Shiley-Marcos Alzheimer's Disease Research Center at the University of California San Diego are about to launch a Phase 2 clinical trial to test a gene therapy treatment for Alzheimer's disease (AD) called CERE-110.
Bayer HealthCare and Onyx Pharmaceuticals today announced that Bayer HealthCare has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the oral multi-kinase inhibitor regorafenib for the treatment of metastatic and/or unresectable gastrointestinal stromal tumors (GIST) in patients whose disease has progressed despite prior treatment.
Quidel Corporation (NASDAQ: QDEL), a global leader in point-of-care (POC) rapid diagnostic tests, received Special 510(k) clearance for an update to the Company's QuickVue® Influenza A+B test package insert to include reactivity with culture isolates of the 2009 H1N1 Influenza A virus.
› Verified 7 days ago
| Entity Name | St Cloud Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1043269798 PECOS PAC ID: 4880594779 Enrollment ID: O20110221000134 |
News Archive
Although cannabis, also known as marijuana, has been shown to impair memory, reaction time and attention, it is difficult to assess this impairment in a natural setting. Researchers have developed a prototype app called 'Am I Stoned' that could help cannabis users understand how the drug is affecting them through a series of phone-based tasks.
Researchers at the Shiley-Marcos Alzheimer's Disease Research Center at the University of California San Diego are about to launch a Phase 2 clinical trial to test a gene therapy treatment for Alzheimer's disease (AD) called CERE-110.
Bayer HealthCare and Onyx Pharmaceuticals today announced that Bayer HealthCare has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the oral multi-kinase inhibitor regorafenib for the treatment of metastatic and/or unresectable gastrointestinal stromal tumors (GIST) in patients whose disease has progressed despite prior treatment.
Quidel Corporation (NASDAQ: QDEL), a global leader in point-of-care (POC) rapid diagnostic tests, received Special 510(k) clearance for an update to the Company's QuickVue® Influenza A+B test package insert to include reactivity with culture isolates of the 2009 H1N1 Influenza A virus.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jennifer Ann Tarpenning, MD 1555 Northway Dr Ste 200, Saint Cloud, MN 56303-4913 Ph: (320) 240-3157 | Jennifer Ann Tarpenning, MD 1555 Northway Dr Ste 200, Saint Cloud, MN 56303-4913 Ph: (320) 240-3157 |
News Archive
Although cannabis, also known as marijuana, has been shown to impair memory, reaction time and attention, it is difficult to assess this impairment in a natural setting. Researchers have developed a prototype app called 'Am I Stoned' that could help cannabis users understand how the drug is affecting them through a series of phone-based tasks.
Researchers at the Shiley-Marcos Alzheimer's Disease Research Center at the University of California San Diego are about to launch a Phase 2 clinical trial to test a gene therapy treatment for Alzheimer's disease (AD) called CERE-110.
Bayer HealthCare and Onyx Pharmaceuticals today announced that Bayer HealthCare has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the oral multi-kinase inhibitor regorafenib for the treatment of metastatic and/or unresectable gastrointestinal stromal tumors (GIST) in patients whose disease has progressed despite prior treatment.
Quidel Corporation (NASDAQ: QDEL), a global leader in point-of-care (POC) rapid diagnostic tests, received Special 510(k) clearance for an update to the Company's QuickVue® Influenza A+B test package insert to include reactivity with culture isolates of the 2009 H1N1 Influenza A virus.
› Verified 7 days ago
Steven Danielson, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 251 County Rd 120, Saint Cloud, MN 56303 Phone: 320-202-8949 Fax: 320-202-0756 | |
Fariha Furqan Qureshi, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 1555 Northway Dr Ste 200, Saint Cloud, MN 56303 Phone: 320-240-3157 | |
Dr. Crispin Rabara Domingo Jr., M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 4801 Veterans Dr, Saint Cloud, MN 56303 Phone: 320-252-1670 Fax: 320-355-6359 | |
Dr. Bartley Brandon Mueller, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1301 33rd St S, Saint Cloud, MN 56301 Phone: 320-202-8949 Fax: 320-202-0756 | |
Ashley Marie Mackinac, FNP Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 4801 Veterans Dr, Saint Cloud, MN 56303 Phone: 167-032-0252 | |
Steven Weno, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 251 County Road 120, Saint Cloud, MN 56303 Phone: 320-202-8949 Fax: 320-202-0756 |